du Bois A - Search Results

1

Impact of treatment guidelines and implementation of a quality assurance program on quality of care in endometrial cancer.

du Bois A, Strutas D, Buhrmann C, Traut A, Ewald-Riegler N, Kommoss S, Gomez R, Harter P. du Bois A, et al. Onkologie. 2009 Sep;32(8-9):493-8. doi: 10.1159/000226146. Epub 2009 Jul 31. Onkologie. 2009. PMID: 19745593

2

[First-line therapy in ovarian cancer].

du Bois A, Pfisterer J. du Bois A, et al. Zentralbl Gynakol. 2004 Oct;126(5):312-4. doi: 10.1055/s-2004-820390. Zentralbl Gynakol. 2004. PMID: 15478049 Review. German.

3

Why institutions do not participate in ovarian cancer trials -- results from a survey in Germany.

Sehouli J, Kostromitskaia J, Stengel D, du Bois A. Sehouli J, et al. Among authors: du bois a. Onkologie. 2005 Jan;28(1):13-7. doi: 10.1159/000082183. Onkologie. 2005. PMID: 15591726

4

[The Quality Assurance Program of the AGO Organkommission OVAR (QS-OVAR): Pattern of Care and Reality in Germany 2001].

du Bois A, Rochon J, Lamparter C, Pfisterer J. du Bois A, et al. Zentralbl Gynakol. 2005 Feb;127(1):9-17. doi: 10.1055/s-2005-836289. Zentralbl Gynakol. 2005. PMID: 15702446 German.

5

[Impact of center characteristics on outcome in ovarian cancer in Germany].

du Bois A, Rochon J, Lamparter C, Pfisterer J. du Bois A, et al. Zentralbl Gynakol. 2005 Feb;127(1):18-30. doi: 10.1055/s-2005-836290. Zentralbl Gynakol. 2005. PMID: 15702447 German.

6

Survival benefit for patients with advanced-stage transitional cell carcinomas vs. other subtypes of ovarian carcinoma after chemotherapy with platinum and paclitaxel.

Kommoss F, Kommoss S, Schmidt D, Trunk MJ, Pfisterer J, du Bois A; Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom. Kommoss F, et al. Among authors: du bois a. Gynecol Oncol. 2005 Apr;97(1):195-9. doi: 10.1016/j.ygyno.2004.12.047. Gynecol Oncol. 2005. PMID: 15790458 Clinical Trial.

7

Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer.

Du Bois A, Rochon J, Lamparter C, Pfisterer J; AGO Organkommission OVAR PFisterer. Du Bois A, et al. Int J Gynecol Cancer. 2005 Mar-Apr;15(2):183-91. doi: 10.1111/j.1525-1438.2005.15202.x. Int J Gynecol Cancer. 2005. PMID: 15823098 Free article. Review.

8

Non-enrolment of ovarian cancer patients in clinical trials: reasons and background.

Harter P, du Bois A, Schade-Brittinger C, Burges A, Wollschlaeger K, Gropp M, Schmalfeldt B, Huober J, Staehle A, Pfisterer J. Harter P, et al. Among authors: du bois a. Ann Oncol. 2005 Nov;16(11):1801-5. doi: 10.1093/annonc/mdi367. Epub 2005 Aug 9. Ann Oncol. 2005. PMID: 16091427 Free article.

9

Cisplatinum rechallenge in relapsed ovarian cancer patients with platinum reinduction therapy and carboplatin hypersensitivity.

Kandel MJ, Loehr A, Harter P, Traut A, Gnauert K, du Bois A. Kandel MJ, et al. Among authors: du bois a. Int J Gynecol Cancer. 2005 Sep-Oct;15(5):780-4. doi: 10.1111/j.1525-1438.2005.00136.x. Int J Gynecol Cancer. 2005. PMID: 16174224 Free article.

10

Chemotherapy may be more effective in highly proliferative ovarian carcinomas--a translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol).

Kommoss S, du Bois A, Schmidt D, Parwaresch R, Pfisterer J, Kommoss F. Kommoss S, et al. Among authors: du bois a. Gynecol Oncol. 2006 Oct;103(1):67-71. doi: 10.1016/j.ygyno.2006.01.037. Epub 2006 Mar 3. Gynecol Oncol. 2006. PMID: 16516280

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

561 results

Search Page